NAV

Prostalene

This drug entry is astuband has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Prostalene
DrugBank Accession Number
DB11454
Background

Analog of prostaglandin F2 alpha.

Type
Small Molecule
Groups
Vet approved
Structure
MOL SDF PDB SMILES InChI
Similar Structures
Weight
Average: 380.525
Monoisotopic: 380.256274259
Chemical Formula
C22H36O5
Synonyms
  • Prostalene
  • Prostaleno
External IDs
  • RS-9390
  • RS9390

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information oncontraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including:blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRsBrowse all" title="" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug InteractionsLearn More" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction
Integrate drug-drug
interactions in your software
Aceclofenac Prostalene可以12月的治疗效果eased when used in combination with Aceclofenac.
Acemetacin Prostalene可以12月的治疗效果eased when used in combination with Acemetacin.
Acetylsalicylic acid Prostalene可以12月的治疗效果eased when used in combination with Acetylsalicylic acid.
Alclofenac Prostalene可以12月的治疗效果eased when used in combination with Alclofenac.
Aminophenazone Prostalene可以12月的治疗效果eased when used in combination with Aminophenazone.
Antipyrine Prostalene可以12月的治疗效果eased when used in combination with Antipyrine.
Antrafenine Prostalene可以12月的治疗效果eased when used in combination with Antrafenine.
Balsalazide Prostalene可以12月的治疗效果eased when used in combination with Balsalazide.
Benorilate Prostalene可以12月的治疗效果eased when used in combination with Benorilate.
Benoxaprofen Prostalene可以12月的治疗效果eased when used in combination with Benoxaprofen.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Synchrocept

Categories

Drug Categories
Chemical TaxonomyProvided byClassyfire
Description
This compound belongs to the class of organic compounds known as fatty acid methyl esters. These are compounds containing a fatty acid that is esterified with a methyl group. They have the general structure RC(=O)OR', where R=fatty aliphatic tail or organyl group and R'=methyl group.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Fatty Acyls
Sub Class
Fatty acid esters
Direct Parent
Fatty acid methyl esters
Alternative Parents
Cyclopentanols/Tertiary alcohols/Methyl esters/Cyclic alcohols and derivatives/Monocarboxylic acids and derivatives/Organic oxides/Hydrocarbon derivatives/Carbonyl compounds
Substituents
Alcohol/Aliphatic homomonocyclic compound/Carbonyl group/Carboxylic acid derivative/Carboxylic acid ester/Cyclic alcohol/Cyclopentanol/Fatty acid methyl ester/Hydrocarbon derivative/Methyl ester
Molecular Framework
Aliphatic homomonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
O02SWY8981
CAS number
54120-61-5
InChI Key
GNIYHUSSKSFYBD-MFZPGRHISA-N
InChI
InChI=1S/C22H36O5/c1-4-5-10-14-22(2,26)15-13-18-17(19(23)16-20(18)24)11-8-6-7-9-12-21(25)27-3/h7-8,13,15,17-20,23-24,26H,4-5,9-12,14,16H2,1-3H3/b15-13+/t6?,17-,18-,19+,20-,22-/m1/s1
IUPAC Name
methyl 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-3-methyloct-1-en-1-yl]cyclopentyl]hepta-4,5-dienoate
SMILES
CCCCC[C@@](C)(O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=C=CCCC(=O)OC

References

一般引用
  1. Ley WB, Purswell BJ, Bowen JM: The effects of prostalene and alfaprostol as uterine myotonics, and the effect on postpartum pregnancy rate in the mare following daily treatment with prostalene. Theriogenology. 1988;29(5):1113-21. [Article]
  2. Averkin G, Schiltz R: Summary of the effect of prostalene, a new synthetic prostaglandin, on the breeding efficiency of mares. Vet Med Small Anim Clin. 1976 Nov;71(11):1616, 1621-3. [Article]
  3. Vickery BH, McRae GI, Bajka A: Luteolysis and termination of early pregnancy in the rhesus monkey with prostalene, a synthetic prostaglandin analog. Prostaglandins Med. 1979 Mar;2(3):191-201. [Article]
  4. Bosu WT, McKinnon AO: Induction of abortion during midgestation in mares. Can Vet J. 1982 Dec;23(12):358-60. [Article]
  5. Hamm D, Witherspoon DM, Buell JR, Chen CL, Jochle W: Determination of clinical and luteolytic effectiveness of a prostaglandin analog in mares by a dose response study. Theriogenology. 1981 Oct;16(4):447-57. [Article]
  6. Loy RG, Buell JR, Stevenson W, Hamm D: Sources of variation in response intervals after prostaglandin treatment in mares with functional corpora lutea. J Reprod Fertil Suppl. 1979;(27):229-35. [Article]
  7. Imel KJ, Squires EL, Elsden RP, Shideler RK: Collection and transfer of equine embryos. J Am Vet Med Assoc. 1981 Nov 15;179(10):987-91. [Article]
  8. Vickery B, Briones W, Holstein A: Opposite and mutually antagonistic effects on uterine contractility of two epimeric forms of a synthetic prostaglandin analog. Prostaglandins Med. 1979 Jan;2(1):3-10. [Article]
KEGG Drug
D05642
ChemSpider
4940711
ZINC
ZINC000005513458

Clinical Trials

Clinical TrialsLearn More" title="" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
Property Value Source
Water Solubility 0.0288 mg/mL ALOGPS
logP 3.65 ALOGPS
logP 2.83 Chemaxon
logS -4.1 ALOGPS
pKa (Strongest Acidic) 14.51 Chemaxon
pKa (Strongest Basic) -1.3 Chemaxon
Physiological Charge 0 Chemaxon
Hydrogen Acceptor Count 4 Chemaxon
Hydrogen Donor Count 3 Chemaxon
Polar Surface Area 86.99 Å2 Chemaxon
Rotatable Bond Count 12 Chemaxon
Refractivity 109.56 m3·mol-1 Chemaxon
Polarizability 44.39 Å3 Chemaxon
Number of Rings 1 Chemaxon
Bioavailability 1 Chemaxon
Rule of Five Yes Chemaxon
Ghose Filter Yes Chemaxon
Veber's Rule No Chemaxon
医学博士DR-like Rule No Chemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Spectrum Spectrum Type Splash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available

Drug created at February 25, 2016 18:53 / Updated at February 21, 2021 18:53